Skip to main content
Clinical Trials/NCT07380178
NCT07380178
Completed
Not Applicable

The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis

Universitas Sebelas Maret1 site in 1 country40 target enrollmentStarted: April 1, 2025Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
Total Nasal Symptom Score (TNSS)

Overview

Brief Summary

This study was conducted to see before and after treatment whether it provided improvement in the patient's clinical symptoms.

Detailed Description

This research is the first to be conducted with preliminary research on humans.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
None

Masking Description

Department Biomedic and Science Universitas Sebelas Maret Surakarta Indonesia, Department Pharmacy Universitas Muhammadiyah Surakarta Indonesia, Universitas Sebelas Maret Hospital Sukoharjo Indonesia

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged 18 - 60 years who have signed an informed consent
  • Diagnosed with persistent allergic rhinitis with a Skin Prick Test or Positive IgE Examination.

Exclusion Criteria

  • The presence of complications in the nose such as nasal septum deviation, polyps, rhinosinusitis
  • Have undergone specific immunotherapy for 2 years
  • Use of drugs that affect allergy test results: antihistamines, corticosteroids, antihypertensive drugs, and decongestants
  • Pregnancy and Breastfeeding

Arms & Interventions

Control Group

Experimental

Loratadine 10 mg/day and Fluticasone Furoate 27.5 mcg twice daily.

Intervention: Loratadine 10 Mg (Other)

Control Group

Experimental

Loratadine 10 mg/day and Fluticasone Furoate 27.5 mcg twice daily.

Intervention: Fluticasone Furoate (Other)

Treatment A: Quercetin 100 mg

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 100 mg/day.

Intervention: Quercetin (Other)

Treatment A: Quercetin 100 mg

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 100 mg/day.

Intervention: Loratadine 10 Mg (Other)

Treatment A: Quercetin 100 mg

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 100 mg/day.

Intervention: Fluticasone Furoate (Other)

High-Dose Quercetin

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 200 mg/day.

Intervention: Quercetin (Other)

High-Dose Quercetin

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 200 mg/day.

Intervention: Loratadine 10 Mg (Other)

High-Dose Quercetin

Experimental

Loratadine 10 mg/day, Fluticasone Furoate 27.5 mcg twice daily, and Quercetin 200 mg/day.

Intervention: Fluticasone Furoate (Other)

Apple Extract Only

Experimental

Apple fruit extract (Malus sylvestris Mill) and Quercetin 200 mg/day.

Intervention: Quercetin (Other)

Apple Extract Only

Experimental

Apple fruit extract (Malus sylvestris Mill) and Quercetin 200 mg/day.

Intervention: Apple Extract (Other)

Outcomes

Primary Outcomes

Total Nasal Symptom Score (TNSS)

Time Frame: Baseline, Month 3, and Month 6

The TNSS evaluates the severity of four nasal symptoms: nasal congestion, sneezing, nasal itching, and rhinorrhea. Each symptom is rated on a 4-point scale: 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The total score is the sum of the four individual symptom scores, ranging from 0 to 12. Higher scores indicate worse symptom severity.

Secondary Outcomes

  • Serum Interleukin-6 (IL-6) Levels(Baseline, Month 3, and Month 6)
  • Malondialdehyde (MDA) Levels(Baseline, Month 3, and Month 6)
  • Nuclear Factor-Kappa Beta (NF-kB) Expression(Baseline, Month 3, and Month 6)
  • Serum Interleukin-8 (IL-8) Levels(Baseline, Month 3, and Month 6)
  • Serum TNF-alpha Levels(Baseline, Month 3, and Month 6)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Niken Dyah Aryani Kuncorowati

Otolaryngologist (ENT Specialist)

Universitas Sebelas Maret

Study Sites (1)

Loading locations...

Similar Trials